Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

Blood

Volumn 97, Issue 3, 2001, Pages 631-637

  Giralt, Sergio ^a   Thall, Peter F ^a   Khouri, Issa ^a   Wang, Xuemei ^a   Braunschweig, Ira ^a   Ippolitti, Cindy ^a   Claxton, David ^a   Donato, Michele ^a   Bruton, Jill ^a   Cohen, Agueda ^a   Davis, Marilyn ^a   Andersson, Borje S ^a   Anderlini, Paolo ^a   Gajewski, James ^a   Kornblau, Steven ^a   Andreeff, Michael ^a   Przepiorka, Donna ^a   Ueno, Naoto T ^a   Molldrem, Jeff ^a   Champlin, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; FLUDARABINE; MELPHALAN; PURINE DERIVATIVE; TACROLIMUS;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 0035254219     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.3.631     Document Type: Article

References (39)

1. Report from the International Bone Marrow Transplant Registry
2. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s
3. Bone marrow transplantation
4. Outcome after allogeneic bone marrow transplant for leukemia in older adults
5. Bone marrow transplantation in patients aged 45 years and older
6. The frequency of long-term remission in patients with acute myelogenous leukemia treated with conventional maintenance chemotherapy: A study of 760 patients with a minimal follow-up time of 6 years
7. Response to salvage therapy and survival after relapse in acute myelogenous leukemia
8. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
9. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
10. The systemic administration of intravenous melphalan
11. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: Alloengraftment with potential preservation of fertility in women
12. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: Induction of synergistic cytotoxicity independent of reversal of apoptosis resistance
13. Nonparametric estimation from incomplete observations
14. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors
15. Chronic graft-versus-host disease syndrome in man: A long term clinical pathologic study of 20 Seattle patients
16. An international system for human cytogenetic nomenclature 20 (1978 ISCN)
17. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation
18. Regimen related toxicities in patients undergoing bone marrow transplantation
19. 2 measures the discrepancy between observation and hypothesis
20. The exact analysis of contingency tables in medical research
21. Evaluation of survival data and two new rank order statistics arising in its consideration
22. Regression models and life tables
23. Proportional hazards tests and diagnostics based on weighted residuals
24. Robust locally-weighted regression and smoothing scatterplots
25. A comparison of some approximate confidence intervals for the binomial parameter
26. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after highdose melphalan in patients with multiple myeloma
27. Dose escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies
28. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia
29. Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults
30. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
31. A nonmyeloablative regimen for allografting highrisk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy
32. Induction of graft-vs-leukemia as primary treatment of chronic myelogenous leukemia
33. Outpatient PBSC allografts using immunosuppression with low dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant
34. Hematopoietic stem cell transplantation in older adults